July 29, 2014 6:13 PM ET

Biotechnology

Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate includes the EBI-005, a novel IL-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and in Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of retinal diseases, such ...

215 First Street

Suite 400

Cambridge, MA 02142

United States

Founded in 2008

15 Employees

Phone:

617-871-9911

Fax:

617-858-0911

Key Executives for Eleven Biotherapeutics, Inc.

Chief Executive Officer
Age: 55
Total Annual Compensation: $459.4K
Chief Development Officer
Age: 52
Total Annual Compensation: $198.0K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $344.5K
Compensation as of Fiscal Year 2013.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Eleven Biotherapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net loss and comprehensive loss was $7,222,000, net loss applicable to common stockholders was $7,741,000 or $0.80 per basic and diluted against net loss and comprehensive loss was $5,512,000, net loss applicable to common stockholders was $6,405,000 or $5.14 per basic and diluted a year ago. Collaboration revenue was $568,000. Loss from operations was $7,189,000 compared to $5,435,000 a year ago.

Eleven Biotherapeutics, Inc. to Report Q1, 2014 Results on May 15, 2014

Eleven Biotherapeutics, Inc. announced that they will report Q1, 2014 results on May 15, 2014

Eleven Biotherapeutics, Inc., Q1 2014 Earnings Call, May 15, 2014

Eleven Biotherapeutics, Inc., Q1 2014 Earnings Call, May 15, 2014

Similar Private Companies By Industry

Company Name Region
MJ GeneWorks, Inc. United States
BioSurface Technologies Corporation United States
Stem Genetics Inc United States
Sirna Therapeutics, Inc. United States
Saigene Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 4, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.